Fact Sheet: The Circulating Cell-free Genome Atlas (CCGA) Study

Developing a single blood test for the early detection of multiple deadly cancer types is a challenging endeavor for many reasons, including complex cancer biology.

GRAIL is developing technology to attempt to overcome these challenges using the power of next-generation sequencing, machine learning, and data science. Through a robust and rigorous clinical study program, which includes our foundational study, the Circulating Cell-free Genome Atlas (CCGA) study, we are working to make a multi-cancer early detection blood test a reality.